Lordick, F. and Lorenzen, S. and Stollfuss, J. and Vehling-Kaiser, U. and Kullmann, Frank and Hentrich, M. and Zumschlinge, R. and Dietzfelbinger, H. and Thoedtmann, J. and Hennig, M. and Seroneit, T. and Bredenkamp, R. and Duyster, J. and Peschel, C. (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. BRITISH JOURNAL OF CANCER, 93 (2). pp. 190-194. ISSN 0007-0920,
Full text not available from this repository. (Request a copy)Abstract
Oxaliplatin plus fluorouracil/folinic acid (5-FU/FA) every 2 weeks has shown promising activity in advanced gastric cancer. This study assessed the efficacy and safety of weekly oxaliplatin plus 5-FU/FA (FUFOX regimen) in the metastatic setting. Patients with previously untreated metastatic gastric cancer received oxaliplatin (50 mg m(-2)) plus FA (500 mg m(-2), 2-h infusion) followed by 5-FU (2000 mg m(-2), 24-h infusion) given on days 1, 8, 15 and 22 of a 5- week cycle. The primary end point of this multicentre phase II study was the response rate according to RECIST criteria. A total of 48 patients were enrolled. Median age was 62 years and all patients had metastatic disease, with a median number of three involved organs. The most common treatment-related grade 3/4 adverse events were diarrhoea (17%), deep vein thrombosis (15%), neutropenia (8%), nausea (6%), febrile neutropenia (4%), fatigue ( 4%), anaemia ( 4%), tumour bleeding ( 4%), emesis (2%), cardiac ischaemia ( 2%) and pneumonia ( 2%). Grade 1/2 sensory neuropathy occurred in 67% of patients but there were no episodes of grade 3 neuropathy. Intent-to-treat analysis showed a response rate of 54% (95% CI, 39-69%), including two complete responses. At a median follow-up of 18.1 months ( range 11.2-26.2 months), median survival is 11.4 months ( 95% CI, 8.0-14.9 months) and the median time to progression is 6.5 months ( 95% CI, 3.9-9.2 months). The weekly FUFOX regimen is well tolerated and shows notable activity as first-line treatment in metastatic gastric cancer. (c) 2005 Cancer Research UK.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | COLORECTAL-CANCER; RANDOMIZED-TRIAL; RECTAL-CANCER; LEUCOVORIN; CARCINOMA; ADENOCARCINOMA; ESOPHAGEAL; IRINOTECAN; CISPLATIN; RADIATION; oxaliplatin; fluorouracil; metastatic gastric cancer; first-line |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 May 2021 07:12 |
| Last Modified: | 04 May 2021 07:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/35869 |
Actions (login required)
 |
View Item |
